Datapoint: Keytruda Scores First-Line Esophageal Cancer Nod

The FDA last week approved Merck & Co.’s Keytruda for the treatment of newly diagnosed esophageal or gastroesophageal junction carcinoma in tandem with chemotherapy. Keytruda is the first PD-1/L1 agent to be approved as a first-line therapy for this type of cancer. The drug was approved as a third-line treatment for gastric or gastroesophageal junction cancer in 2017, an indication where it holds preferred formulary placement for 6% of covered lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 3/24/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 26

Datapoint: Oscar Partners With Colorado Health Systems in Statewide Expansion Effort

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 25

Datapoint: Kaiser Dominates 2022 Star Ratings

https://www.mmitnetwork.com/wp-content/uploads/2021/08/post-default-img.jpg
October 18

Datapoint: AmeriHealth Caritas to Enter Exchange Market

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today